drugset / Trial / NCT06727721

Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

NCT06727721

Phase 2 Recruiting 10 enrolled Lu jin ,MD
RandomizedParallel-groupTriple-blindTreatment

Summary

Umbilical cord mesenchymal stem cell injection expressing OCN19, while playing the role of MSCs, can directly stimulate the expression of insulin gene and the division and proliferation of islet beta cells, which is expected to further enhance the therapeutic effect of stem cells. In non-clinical studies, it was found that MSCs expressing OCN19 had better hypoglycemic effect than MSCs

Timeline

Start
2023-11-06
Primary completion
2028-12-12
Completion
2029-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells Cell therapy
Comparator mesenchymal stem cells Cell therapy